Krishna Institute of Medical Sciences Ltd
Snapshot View

1285.15 +12.40 ▲1.0%

24 May 2022, 04:01:00 PM
Volume: 1,545

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website
Market Cap 10,281.57 Cr.
Enterprise Value(EV) 10,255.74 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 41.57 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 30.91 Trailing Twelve Months Ending 2022-03
Industry PE 40.42 Trailing Twelve Months Ending 2022-03
Book Value / Share 173.35 Trailing Twelve Months Ending 2022-03
Price to Book Value 7.41 Calculated using Price: 1,285.15
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 8.00 Cr. 80,027,787 Shares
FaceValue 10
Company Profile

Krishna Institute of Medical Sciences is one of the largest corporate healthcare groups in AP and Telangana in terms of number of patients treated and treatments offered. It also provides multi-disciplinary integrated healthcare services, with a focus on primary secondary & tertiary care in Tier 2-3 cities and primary, secondary, tertiary and quaternary healthcare in Tier 1 cities. It operates multi-specialty hospitals under the “KIMS Hospitals” brand. It also offers a comprehensive range of healthcare services across specialties and super specialties, including cardiac sciences, oncology, neurosciences, gastric sciences, orthopaedics, organ transplantation, renal sciences and mother & child care.

The company strives to provide quality service to more patients, and it has scope for additional patients and improved occupancy rates. It strategically focuses on the southern India healthcare market where it has a strong understanding of regional nuances, customer culture and the mindset of medical professionals and where there is significant and growing need for quality and affordable healthcare services. Each of its hospitals also has integrated diagnostic services and pharmacies that cater to its patients. Affordability and quality of healthcare services provided by it and its track record of building long-term relationships with medical professionals including its doctors, has enabled growth and helped it build its ‘KIMS Hospitals’ brand. It operates and manages all of its hospitals, which provides it with greater control over its facilities and helps it to better deliver high quality and affordable healthcare services.

Business area of the company

The company offers a comprehensive range of healthcare services including oncology, cardiac sciences, neurosciences, gastric sciences, orthopaedics, renal sciences, organ transplantation, and mother & child care.

Awards and Accreditations

  • 2008: KIMS Secunderabad received its first ISO 9001-2008 certification from AQA International LLC.
  • 2011: KIMS Secunderabad received its first accreditation from NABH.
  • 2015: KIMS Secunderabad was awarded the ‘Healthcare Excellence Award’ by the Indo Global Healthcare Summit and Expo.
  • 2015: KIMS Secunderabad was awarded ‘Nursing Excellence’ award by AHPI.
  • 2015: KIMS Secunderabad was accredited with ISO 9001:2015 certification.
  • 2017: KIMS Secunderabad was awarded by AHPI as a ‘Patient Friendly Hospital’.
  • 2017: KIMS Secunderabad became laureate of the Asia Pacific Society of Infection Control CSSD Center of Excellence Silver Award 2015-2016.
  • 2017: KIMS Secunderabad was awarded ‘Best Hospital of the Year’ in the multispecialty hospital category in Hyderabad and eight other specialities by Times Healthcare Achievers Awards.
  • 2019: 2019 KIMS Secunderabad received certificate of excellence in the category of ‘Best Super-Speciality Hospital in Telangana’ at the National Quality Excellence Awards, 2019 hosted by Praxis Media Institute.
  • 2019: KIMS Secunderabad was awarded ‘Best Hospital to Work For’ from AHPI Global Conclave.
  • 2019: KIMS Secunderabad was accredited by NABL.
  • 2019: KIMS Nellore was issued a certificate of accreditation by NABH for being compliant with NABH pre-accreditation entry level hospital requirements.
  • 2020: KIMS Secunderabad ranked the third best hospital in Hyderabad by The Week magazine.
  • 2020: KIMS Kondapur was accredited with a certificate of assessment for exhibition of its intent and commitment towards ensuring safety and hygiene at workplace by IRClass Systems and Solutions.
  • 2021: The cardiology, emergency and trauma, nephrology and neuroscience departments of KIMS Hyderabad were ranked first in the Hyderabad Multi Speciality category in the Times of India, Hyderabad, All India Critical Care Hospital Ranking Survey, 2021.
  • 2021: The emergency and trauma and nephrology departments of KIMS Hyderabad were ranked second in the South Multi Speciality Category in the Times of India, Hyderabad, All India Critical Care Hospital Ranking Survey, 2021.

Major events and milestones

  • 2000: KIMS Nellore established by BRMH. The business division of BRMH, including the hospital, was transferred to our Company pursuant to the 2012 Scheme.
  • 2004: KIMS Secunderabad established by Company.
  • 2010: Investment by Milestone Private Equity Fund (“MPEF”) in Company.
  • 2014: Acquisition of 57.83% of the equity shareholding of Arunodaya Hospitals.
  • 2015: Investment by India Advantage Fund (IAF) and Emerging India Fund (EIF) and exit of MPEF from our Company pursuant to the share purchase agreement dated June 23, 2014 entered into between, amongst others, IAF, EIF and MPEF.
  • 2017: Acquisition of KIMS Ongole by way of slump sale agreement.
  • 2019: Acquisition of 51% of the equity shareholding of ICIMSPL.
  • 2019: Acquisition of 80% of the equity shareholding of SIMSPL.
  • 2019: Investment by General Atlantic in our Company and exit of IAF and EIF from our Company pursuant to the share purchase agreement dated June 14, 2018 entered into between, amongst others, General Atlantic, IAF and EIF.
  • 2020: Acquisition of 55% of the equity shareholding of KHKPL.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.97%
1 Week
+0.62%
1 Month
-6.14%
3 Month
+6.55%
6 Month
+7.86%
1 Year
2 Year
5 Year
10 Year
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 9.53 2.25 3.31 11.15 -94.27 -25.44 20.22 28.12
Return on Capital Employed (%) 9.81 10.41 9.91 14.96 5.18 12.42 4.99 21.17 30.82
Return on Assets (%) 3.22 0.73 1.11 4.23 -9.91 -5.71 -4.80 9.97 15.64

Balance Sheet View Details

Particulars 4 years 2015-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03* Rs. Cr.
Shh. Funds 238 598 864 1,387
Non Curr. Liab. 243 364 279 278
Curr. Liab. 170 219 278 215
Minority Int. 6 13 12 23
Equity & Liab. 657 1,194 1,433 1,904
Non Curr. Assets 557 975 982 1,511
Curr. Assets 101 220 451 393
Misc. Exp. not W/O
Total Assets 657 1,194 1,433 1,904

Profit Loss View Details

Particulars 4 years 2015-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. TTM
Net Sales 420 1,123 1,330 1,651
Other Income 4 6 10 20
Total Income 424 1,129 1,340 1,671
Total Expenditure -342 -873 -954 -1,135
PBIDT 81 256 386 536
Interest -35 -44 -37 -16
Depreciation -32 -71 -70 -73
Taxation -7 -25 -74 -113
Exceptional Items
PAT 7 115 205 334
Minority Interest -1 4 -4 -8
Share Associate -1 10
Other Related Items
Consolidated Net Profit 6 119 201 336
Adjusted EPS 6 16 26 42

Cash Flow View Details

Particulars 2 years 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 202 356
Cash Fr. Inv. -125 -354
Cash Fr. Finan. -44 10
Net Change 32 12
Cash & Cash Eqvt 41 52

Shareholding Pattern View Details

9 Qtrs 2016-08 (%) 2017-08 (%) 2018-09 (%) 2019-03 (%) 2020-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 55.75 54.80 54.80 46.01 44.59 38.84 38.84 38.84 38.84
Public 44.25 45.20 45.20 53.99 55.41 61.16 61.16 61.16 61.16
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 13.45 13.45 14.86

Announcements View Details

Tue, 24 May 2022
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 & 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and with reference to our Results conference call intimation dated April 17 2022 Please be informed that the Results conference call for Q4 FY22 was hosted on April 20 2022 and the web link for the audio recording of the conference call is as follows:https://www.kimshospitals.com/stakeholder-relations/
Tue, 24 May 2022
Announcement under Regulation 30 (LODR)-Investor Presentation
Krishna Institute of Medical Sciences Limited submits revised Investor Presentation.
Tue, 24 May 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication
Krishna Institute of Medical Sciences Limited submits revised Investor Presentation

Technical Scans View Details

Tue, 24 May 2022
Closing Above Previous High Closing Above Previous High
High Decrease 1 Month High Decrease 1 Month
Closing Near 200 SMA Closing Near 200 SMA
Closing Near 20 SMA Closing Near 20 SMA
MFI Trending Up MFI Trending Up

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,371.20 914.30 -0.8%
Divi's Laboratories Ltd. 97,215.92 3,662.05 -6.0%
Cipla Ltd. 78,341.65 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. 72,413.55 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. 52,337.62 3,640.00 -2.2%
Gland Pharma Ltd. 47,375.00 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. 44,015.42 2,601.25 -0.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.04 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 32.84 3,662.05 -6.0%
Cipla Ltd. Consolidated 2022-03 31.13 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 33.18 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.18 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2022-03 39.10 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 36.11 2,601.25 -0.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 8.29 3,662.05 -6.0%
Cipla Ltd. Consolidated 2022-03 3.76 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.77 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.46 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2022-03 6.62 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 6.81 2,601.25 -0.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 0.10 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,601.25 -0.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 14.13 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,601.25 -0.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 14.13 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,601.25 -0.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 19,159.59 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,601.25 -0.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 2,401.30 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,601.25 -0.6%